FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1090 April 14, 1994 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Dann, E. J. PubMed Citation

To the Editor: In the November 18 issue of the Journal, Dann et al.¹ reported a case of tumor lysis syndrome after treatment with 2-chlorodeoxyadenosine (cladribine) in a patient with refractory chronic lymphocytic leukemia. We would like to report another case of tumor lysis syndrome resulting from treatment with 2-chlorodeoxyadenosine.

A 59-year-old man presented to the Mayo Clinic for a second opinion concerning therapy for his chronic myelogenous leukemia in chronic phase, which had been diagnosed approximately 18 months earlier. The patient could not tolerate hydroxyurea, had dose-limiting thrombocytopenia when treated with busulfan, and did not want to try interferon . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Hansford, J. R, Mulligan, L. M (2000). Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J. Med. Genet. 37: 817-827 [Abstract] [Full Text]  
• Yeung, S.-C. J., Chiu, A. C., Vassilopoulou-Sellin, R., Gagel, R. F. (1998). The Endocrine Effects of Nonhormonal Antineoplastic Therapy. Endocr. Rev. 19: 144-172 [Abstract] [Full Text]